Form 4: Julia P. Gregory, Nurix Therapeutics Director, Reports Stock Option Grant
SEC Form 4 Filing
Director Julia P. Gregory reports the acquisition of stock options in Nurix Therapeutics.
Summary
- On May 20, 2024, Julia P. Gregory, a director of Nurix Therapeutics, Inc., reported the acquisition of 25,000 stock options.
- The options have an exercise price of $16.19.
- The options vest 100% on the earlier of the next annual meeting of the Issuer's stockholders or May 20, 2025, subject to continued service.
- The expiration date for the options is May 19, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a standard disclosure of stock option grants to a company director.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule incentivizes continued service to the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a standard equity compensation practice.
Stakeholder Impact
- The stock option grant aligns the director's interests with shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of transaction: Julia P. Gregory acquired stock options. |
| 05/20/2024 | Date of report filing. |
| 05/20/2025 | Date of full vesting of stock options (earliest possible date). |
| 05/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.